Patient characteristics, MV treatment procedure, and outcome
Patient no.; sex; age, y; diagnosis . | IHC for MV receptors . | . | . | Dose/injection sites/time of injection . | . | Response of distant lesions* . | Overall response, TBI ratio . | . | . | |
|---|---|---|---|---|---|---|---|---|---|---|
| . | CD 46 . | CD 150 . | Previous treatment . | . | Local response* . | . | . | Adverse reactions . | Comments . | |
| 1; M; 65; MF with mucinosis follicularis stage IIb | + | ++ | Tumor excisions, IFN-α, radiotherapy, pegylated interferon, PUVA, topical steroids | 100 TCID50/cervical left/day 4, cycle 1; 100 TCID50/cervical left/day 17, cycle 1; 500 TCID50/cervical left/day 4, cycle 2 = day 32; 500 TCID50/cervical left/day 17, cycle 2 = day 45 | Partial regression of the treated plaque (4×4×0.3 cm) (Figure 3A-B) | Partial regression of distant lesions (Figure 3C-D) | 6.5/21 = 0.3 (PR) | Slight erythema at injection site, itching, stabbing sensation in left shoulder after the first MV injection | none | |
| 2; M; 54; MF stage IIb | ++ | ++ | UV therapy, radiotherapy, PUVA, IFN-α, methotrexate, radiotherapy, topical steroids | 100 TCID50/right thigh/day 4, cycle 1; 100 TCID50/right thigh/day 17, cycle 1; 500 TCID50/right plantar/day 4, cycle 2 = day 32; 500 TCID50/right plantar/day 17, cycle 2 = day 45 | Complete regression of the treated plaque (3×3×0.3 cm) (Figure 3E-F) | Distant tumor (1×1×0.5 cm) became injected lesion and also responded (Figure 3G-H) | 17/18 = 0.94 (SD) | Slight erythema at injection site, dizziness on the day after the first MV injection | Change of injected lesion due to CR | |
| 3; M; 54; lymphomatoid papulosis | + | ++ | Topical steroids, PUVA | 100 TCID50/right upper arm/day 4, cycle 1; 100 TCID50/right upper arm/day 17, cycle 1 | Partial regression of the treated plaque (2.5×2.5×0.3 cm) surrounded by papules (flattening) | Partial regression of distant lesion and new plaque | 16/16 = 1.0 (SD) | None | Discontinued treatment for personal reasons | |
| 4; M; 64; CD30+ pleomorphic large-cell CTCL | ++ | ++ | Tumor excision, radiotherapy, IFN-α, topical steroids, BCNU, Acitretin | 500 TCID50/right plantar/day 4, cycle 1; 500 TCID50/right plantar/day 17, cycle 1; 1000 TCID50/right plantar/day 4, cycle 2 = day 32; 1000 TCID50/right plantar/day 17, cycle 2 = day 45 | Minor response (flattening) of a tumor (1.5×2×0.8 cm) | No response, additional lesions | 24/16 = 1.5 (PD) | Burning sensation, slight erythema, and itching at injection site, arthralgias (day 30/31, eg, after IFN before full dose MV injection) | None | |
| 5; F; 54; MF stage IIb | + | ++ | Radiotherapy, BCNU, Neotigason, PUVA, IFN-α, topical steroids | 500 TCID50/inguinal left/day 4, cycle 1; 500 TCID50/inguinal left/day 17, cycle 1 | Partial regression (flattening) of the treated tumor (3×2×1 cm) | No response, additional lesions | 54/40 = 1.35 (PD) | Itching | Overall progression of disease required treatment with cortico-steroids | |
Patient no.; sex; age, y; diagnosis . | IHC for MV receptors . | . | . | Dose/injection sites/time of injection . | . | Response of distant lesions* . | Overall response, TBI ratio . | . | . | |
|---|---|---|---|---|---|---|---|---|---|---|
| . | CD 46 . | CD 150 . | Previous treatment . | . | Local response* . | . | . | Adverse reactions . | Comments . | |
| 1; M; 65; MF with mucinosis follicularis stage IIb | + | ++ | Tumor excisions, IFN-α, radiotherapy, pegylated interferon, PUVA, topical steroids | 100 TCID50/cervical left/day 4, cycle 1; 100 TCID50/cervical left/day 17, cycle 1; 500 TCID50/cervical left/day 4, cycle 2 = day 32; 500 TCID50/cervical left/day 17, cycle 2 = day 45 | Partial regression of the treated plaque (4×4×0.3 cm) (Figure 3A-B) | Partial regression of distant lesions (Figure 3C-D) | 6.5/21 = 0.3 (PR) | Slight erythema at injection site, itching, stabbing sensation in left shoulder after the first MV injection | none | |
| 2; M; 54; MF stage IIb | ++ | ++ | UV therapy, radiotherapy, PUVA, IFN-α, methotrexate, radiotherapy, topical steroids | 100 TCID50/right thigh/day 4, cycle 1; 100 TCID50/right thigh/day 17, cycle 1; 500 TCID50/right plantar/day 4, cycle 2 = day 32; 500 TCID50/right plantar/day 17, cycle 2 = day 45 | Complete regression of the treated plaque (3×3×0.3 cm) (Figure 3E-F) | Distant tumor (1×1×0.5 cm) became injected lesion and also responded (Figure 3G-H) | 17/18 = 0.94 (SD) | Slight erythema at injection site, dizziness on the day after the first MV injection | Change of injected lesion due to CR | |
| 3; M; 54; lymphomatoid papulosis | + | ++ | Topical steroids, PUVA | 100 TCID50/right upper arm/day 4, cycle 1; 100 TCID50/right upper arm/day 17, cycle 1 | Partial regression of the treated plaque (2.5×2.5×0.3 cm) surrounded by papules (flattening) | Partial regression of distant lesion and new plaque | 16/16 = 1.0 (SD) | None | Discontinued treatment for personal reasons | |
| 4; M; 64; CD30+ pleomorphic large-cell CTCL | ++ | ++ | Tumor excision, radiotherapy, IFN-α, topical steroids, BCNU, Acitretin | 500 TCID50/right plantar/day 4, cycle 1; 500 TCID50/right plantar/day 17, cycle 1; 1000 TCID50/right plantar/day 4, cycle 2 = day 32; 1000 TCID50/right plantar/day 17, cycle 2 = day 45 | Minor response (flattening) of a tumor (1.5×2×0.8 cm) | No response, additional lesions | 24/16 = 1.5 (PD) | Burning sensation, slight erythema, and itching at injection site, arthralgias (day 30/31, eg, after IFN before full dose MV injection) | None | |
| 5; F; 54; MF stage IIb | + | ++ | Radiotherapy, BCNU, Neotigason, PUVA, IFN-α, topical steroids | 500 TCID50/inguinal left/day 4, cycle 1; 500 TCID50/inguinal left/day 17, cycle 1 | Partial regression (flattening) of the treated tumor (3×2×1 cm) | No response, additional lesions | 54/40 = 1.35 (PD) | Itching | Overall progression of disease required treatment with cortico-steroids | |
Characteristics of the 5 patients with CTCL treated within the clinical trial (M indicates male; F, female), pretreatment regimens (PUVA, psoralen + UV-A therapy), expression of surface molecules CD46 and CD150 in immunohistochemistry (IHC: +, positive; ++, strong positive) that can act as receptors for measles virus, doses received during the course of the study, individual responses (SD, stable disease; PD, progressive disease) and adverse reactions.